Clinical Trial Update: Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial investigates the combination of imatinib and LBH589 (panobinostat) for newly diagnosed and recurrent chordoma; current status is unknow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chordoma

Drugs mentioned

• Imatinib (imatinib)
• LBH589 (panobinostat)

Snippet

Sponsor: Deric M Park MD | Conditions: Chordoma | Phase 1 | Status: UNKNOWN